Clinical application of ivonib

Ivosidenib (Ivosidenib), as an IDH1 inhibitor, is mainly used clinically to treat patients with acute myeloid leukemia (AML) who express IDH1 gene mutations. The drug interferes with the metabolic process of leukemia cells by specifically inhibiting the abnormally active IDH1 enzyme, thereby inhibiting cell growth. The clinical application of ivonib is a targeted treatment strategy designed to improve treatment efficacy and reduce damage to healthy tissue, providing an innovative treatment option for AML patients with specific gene mutations. During treatment, doctors will develop an individualized medication plan based on the patient's genotype and condition, and conduct regular monitoring to evaluate efficacy and safety.